{
  "claim_id": "claim_007",
  "claim": "Recombinant HA antigens produced using BEVS have been shown to induce significantly higher levels of broadly cross-reactive antibodies against highly conserved regions of HA compared with egg-derived vaccines.",
  "document": "Zimmerman_et_al.__2023_",
  "verification_stats": {
    "total_extracted": 1,
    "verified": 0,
    "rejected": 1,
    "verification_rate": 0.0
  },
  "verified_evidence": [],
  "rejected_evidence": [
    {
      "id": 1,
      "quote": "because it is not subject to mutations to the A (H3 N2) glycosylation binding site that reduce the effectiveness of egg based vaccines.",
      "reason": "does not support claim",
      "original_explanation": "This quote supports the claim by stating that recombinant HA antigens (as used in RIV4) are not affected by mutations that occur during egg-based vaccine production, which can reduce the effectiveness of egg-derived vaccines. This implies a mechanistic advantage for recombinant vaccines in targeting conserved regions."
    }
  ],
  "model_used": "gpt-4.1"
}